Abstract: Systems, computer program products, and methods are described herein for automatically and dynamically updating and managing authentication credentials in a distributed network. The present disclosure is configured to identify at least one vault identifier, wherein the vault identifier is associated with a vault comprising at least one authentication credential; access, based on the at least one vault identifier, vault data for a vault associated with the vault identifier; generate, based on the at least one vault identifier and the vault data, a vault tree comprising a hierarchical organization of the vault and associated vault dependencies comprising at least one shared authentication credential; and configure, based on the vault tree, a vault rotation user interface with the vault tree, wherein the vault rotation user interface comprises the vault tree at a current time with the at least one shared authentication credential.

Abstract: Systems, methods, and apparatus are provided for dynamic DAG-based blockchain authentication protocols. An authentication engine may deploy two associated parent nodes in a private blockchain network. The first parent node may include first party data and the second parent node may include smart contract logic including an aggregation threshold. The authentication engine may receive transaction data for a plurality of transactions between the first party and a second party and validate the transactions against the aggregation threshold. If a transaction exceeds the aggregation threshold, the authentication engine may aggregate a threshold number of transaction nodes into an aggregated node cryptographically linked to the second parent node and generate a new transaction node including a self-executing smart contract cryptographically linked to the aggregated node.

Abstract: Systems, methods, and apparatus are provided for dynamic DAG-based blockchain authentication protocols. An authentication engine may deploy two associated parent nodes in a private blockchain network. The first parent node may include first party data and the second parent node may include smart contract logic including an aggregation threshold. The authentication engine may receive transaction data for a plurality of transactions between the first party and a second party and validate the transactions against the aggregation threshold. If a transaction exceeds the aggregation threshold, the authentication engine may aggregate a threshold number of transaction nodes into an aggregated node cryptographically linked to the second parent node and generate a new transaction node including a self-executing smart contract cryptographically linked to the aggregated node.

Abstract: Described herein are compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: A communications framework can include a discussion tool operable within a process operations environment, where the discussion tool issues a request for communication with an expert and records contextual information of the process operations environment: a notification tool that, responsive to issuance of the request for communication, calls for issuance of a notification to an identified expert; and a recordation tool that calls for storage of communication information associated with communication with the identified expert to a database.

Abstract: Compounds which are benzoxazolone derivatives are disclosed, including compounds of the following genus: The compounds possess anti-inflammasome properties and exhibit anti-fibrotic and anti-proliferative effects. They are useful in inhibiting the activation of NLRP3 or NLRC4 receptors, and in the treatment of a variety of neuroinflammatory disorders such as autoimmune diseases, type-2 diabetes, Cryopyrin-Associated Autoinflammatory Syndromes, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and rheumatoid arthritis.

Abstract: Described herein are compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1 A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, N—Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1 A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Electronic form (e-form) processing includes generating an e-form based on a form template, the form template being selected from pre-defined form templates. The e-form includes modular sections arranged in a pre-defined order, each modular section being associated with user privileges. Further, data is retrieved from at least one database to partly populate at least one of the modular sections in the e-form. Subsets of the modular sections are provided to designated users based on the user privileges and a workflow associated with the e-form. A processed e-form, including the retrieved data and the data inputs, and having at least one external document, is created based on data inputs received from the designated users. A processed electronic document including the modular sections populated with the retrieved data, the data inputs, and external data from the external document arranged in the pre-defined order is generated from the processed e-form.

Abstract: The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: With rapid population growth and urbanization, emergency services in various cities around the world worry that the current transportation infrastructure is no longer adequate for large-scale evacuations. This disclosure considers how to mitigate this issue through infrastructure upgrades, such as the additions of lanes to road segments and the raising of bridges and roads. This disclosure proposes a MIP model for deciding the most effective infrastructure upgrades as well as a Benders decomposition approach where the master problem jointly plans the upgrades and evacuation routes and the subproblem schedules the evacuation itself.

Abstract: Operations include executing a WebSocket server on a machine executing a web browser; establishing a connection between the WebSocket server and the web browser; receiving, by the WebSocket server from the web browser, a request requiring execution of a local application on the machine; and executing, by the WebSocket server, the local application to serve the request.

Abstract: Operations include executing a WebSocket server on a machine executing a web browser; establishing a connection between the WebSocket server and the web browser; receiving, by the WebSocket server from the web browser, a request requiring execution of a local application on the machine; and executing, by the WebSocket server, the local application to serve the request.

Abstract: Electronic form (e-form) processing includes generating an e-form based on a form template, the form template being selected from pre-defined form templates. The e-form includes modular sections arranged in a pre-defined order, each modular section being associated with user privileges. Further, data is retrieved from at least one database to partly populate at least one of the modular sections in the e-form. Subsets of the modular sections are provided to designated users based on the user privileges and a workflow associated with the e-form. A processed e-form, including the retrieved data and the data inputs, and having at least one external document, is created based on data inputs received from the designated users. A processed electronic document including the modular sections populated with the retrieved data, the data inputs, and external data from the external document arranged in the pre-defined order is generated from the processed e-form.